Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.
about
Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccineBinary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteinsAnthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxinAn alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shockIn vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunityAnalysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assaysInhalational anthrax (Ames aerosol) in naïve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremiaThe role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbedAnthrax vaccination strategiesImmunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis AmesMonoclonal antibody therapies against anthraxRabbit and nonhuman primate models of toxin-targeting human anthrax vaccinesA high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challengeNovel and unique diagnostic biomarkers for Bacillus anthracis infection.Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells.Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.Needle-free skin patch vaccination method for anthrax.Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.Identification of a second collagen-like glycoprotein produced by Bacillus anthracis and demonstration of associated spore-specific sugars.Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challengeEfficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthraxAnthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.Comparison of three anthrax toxin neutralization assaysGenetic vaccines for anthrax based on recombinant adeno-associated virus vectorsRole of purine biosynthesis in Bacillus anthracis pathogenesis and virulence.Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adultsAnthrax lethal factor inhibitionOral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Deep-coverage rhesus red blood cell proteome: a first comparison with the human and mouse red blood cell.Anthrax spores make an essential contribution to vaccine efficacyPossible use of bacteriophages active against Bacillus anthracis and other B. cereus group members in the face of a bioterrorism threat.Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigenEvaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.Evaluation of mucoadhesive carrier adjuvant: toward an oral anthrax vaccine.Development of an improved vaccine for anthraxBacillus anthracis virulence in Guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonalityDefensive applications of gene transfer technology in the face of bioterrorism: DNA-based vaccines and immune targeting.Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.
P2860
Q23912118-8050CDFD-80D7-4619-8D70-8A2BEA300243Q24562788-FA2AABF6-14BC-4E96-86D7-C06B4E8FB3ABQ24796044-EBE513EE-2387-4737-B5A6-3525733D2677Q27486899-40962CC0-0845-4837-8C85-2735F0DBC16EQ28383065-128F9226-F0DB-41A4-85F1-C9844638E3EAQ28383562-42AB023B-52C5-4829-BB3F-BFD0AA0743B7Q28387410-DD771CCF-B16E-4C20-982C-647339486C82Q28391462-DE39228B-8159-4E99-A808-4ED3B372316CQ28392248-EBDB8E90-023C-43CD-99E1-809F1FBB4B29Q28392659-9656A201-185F-4B7D-81ED-4F17480011D6Q28393072-93351650-9F46-4736-8213-D9655F99ED96Q28398013-56D61265-CCBC-4420-BB01-E414F296085EQ28398021-0F1AE11E-518A-4FB0-8A90-46C7464ADF69Q30157179-966376CB-C11F-40E9-B8BF-6CB439868028Q30391848-24DEC181-B9E3-4879-BFBC-0A5F3DC95E80Q30859738-E2A2B832-E1D9-4280-B404-DBE6372C5744Q31037960-E41E793A-8501-4F41-9E7A-5313543A112BQ32066443-CC592C7D-2245-4A58-9F71-37245042DDFFQ33217514-4B2E2FE9-F37D-408A-8101-9D2C4AACF0BFQ33284583-6437A9CD-3119-49EE-9AB9-DE6588B320D2Q33396429-AA724099-622F-48FE-B343-DF6193AB7B43Q33505445-A7FA4E1B-DC71-42E1-9E0B-E6BA43BEEE52Q33550670-E949BFA2-7C9F-49FC-879B-E369E3FD0624Q33713243-D0385AE7-E5DA-4CE3-912E-C3DEAB7B503FQ33735602-DD3DAE15-56A9-49DE-B380-DB98B39B24E7Q33747721-CAFFC2FD-4355-49E0-994B-38C7C21E3609Q33833525-7C69517C-8D0A-422A-AC23-51488DE22214Q33883273-550EED4F-4634-4B57-8967-4CA574D76498Q33962445-2D566BF6-B41D-48AC-B616-920EE9603D04Q34117857-0C63D077-0D4E-492A-9F0B-DA764020EA3AQ34176948-C8927A2F-6442-4BEE-B1DE-B0F13AF67C01Q34334441-F44F8E23-C043-4AE1-9752-2BC89B2A7EA6Q34344419-2A8F4591-D33B-4701-8D4B-ED813DB870FCQ34463262-79503A19-ACA0-48B5-B38A-55BB5EF2BCDDQ34582387-2B3FAE36-2B6B-4F7D-95AF-AE981F8AE094Q34604366-28CC4AD5-E57C-40DA-8CB8-3FDF0D98D701Q34744925-1385405F-8F55-442C-AA30-99FE43FB049EQ34774876-BFF628F8-3902-454D-A813-C08C8B59A1B0Q35594090-5ABA1187-F0B1-4BF0-86F4-4071F04C072FQ35913411-88300730-99EC-4129-9F47-28C0C3A26D33
P2860
Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Efficacy of a human anthrax va ...... f diverse geographical origin.
@en
Efficacy of a human anthrax va ...... f diverse geographical origin.
@nl
type
label
Efficacy of a human anthrax va ...... f diverse geographical origin.
@en
Efficacy of a human anthrax va ...... f diverse geographical origin.
@nl
prefLabel
Efficacy of a human anthrax va ...... f diverse geographical origin.
@en
Efficacy of a human anthrax va ...... f diverse geographical origin.
@nl
P2093
P1433
P1476
Efficacy of a human anthrax va ...... f diverse geographical origin.
@en
P2093
Fellows PF
Friedlander AM
Linscott MK
P304
P356
10.1016/S0264-410X(01)00021-4
P407
P577
2001-04-01T00:00:00Z